Minucci Angelo, De Paolis Elisa, Concolino Paola, De Bonis Maria, Rizza Roberta, Canu Giulia, Scaglione Giovanni Luca, Mignone Flavio, Scambia Giovanni, Zuppi Cecilia, Capoluongo Ettore
Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Teaching and Research Hospital "Agostino Gemelli" Foundation, Rome, Italy.
Laboratory of Clinical Molecular and Personalized Diagnostics, Institute of Biochemistry and Clinical Biochemistry, Teaching and Research Hospital "Agostino Gemelli" Foundation, Rome, Italy.
Clin Chim Acta. 2017 Jul;470:83-92. doi: 10.1016/j.cca.2017.04.026. Epub 2017 Apr 30.
Evaluation of copy number variation (CNV) in BRCA1/2 genes, due to large genomic rearrangements (LGRs), is a mandatory analysis in hereditary breast and ovarian cancers families, if no pathogenic variants are found by sequencing. LGRs cannot be detected by conventional methods and several alternative methods have been developed. Since these approaches are expensive and time consuming, identification of alternative screening methods for LGRs detection is needed in order to reduce and optimize the diagnostic procedure. The aim of this study was to investigate a Competitive PCR-High Resolution Melting Analysis (C-PCR-HRMA) as molecular tool to detect recurrent BRCA1 LGRs.
C-PCR-HRMA was performed on exons 3, 14, 18, 19, 20 and 21 of the BRCA1 gene; exons 4, 6 and 7 of the ALB gene were used as reference fragments.
This study showed that it is possible to identify recurrent BRCA1 LGRs, by melting peak height ratio between target (BRCA1) and reference (ALB) fragments. Furthermore, we underline that a peculiar amplicon-melting profile is associated to a specific BRCA1 LGR. All C-PCR-HRMA results were confirmed by Multiplex ligation-dependent probe amplification.
C-PCR-HRMA has proved to be an innovative, efficient and fast method for BRCA1 LGRs detection. Given the sensitivity, specificity and ease of use, c-PCR-HRMA can be considered an attractive and powerful alternative to other methods for BRCA1 CNVs screening, improving molecular strategies for BRCA testing in the context of Massive Parallel Sequencing.
对于遗传性乳腺癌和卵巢癌家族,如果测序未发现致病变异,评估由大片段基因组重排(LGR)导致的BRCA1/2基因拷贝数变异(CNV)是一项必要分析。传统方法无法检测LGR,因此已开发出多种替代方法。由于这些方法昂贵且耗时,需要鉴定用于检测LGR的替代筛查方法,以减少并优化诊断程序。本研究的目的是探究竞争性PCR-高分辨率熔解分析(C-PCR-HRMA)作为检测复发性BRCA1 LGR的分子工具。
对BRCA1基因的第3、14、18、19、20和21外显子进行C-PCR-HRMA;使用ALB基因的第4、6和7外显子作为参考片段。
本研究表明,通过靶标(BRCA1)和参考(ALB)片段之间的熔解峰高比,可以鉴定复发性BRCA1 LGR。此外,我们强调特定的扩增子熔解图谱与特定的BRCA1 LGR相关。所有C-PCR-HRMA结果均通过多重连接依赖探针扩增得到证实。
C-PCR-HRMA已被证明是一种用于检测BRCA1 LGR的创新、高效且快速的方法。鉴于其敏感性、特异性和易用性,C-PCR-HRMA可被视为BRCA1 CNV筛查其他方法的一种有吸引力且强大的替代方法,在大规模平行测序背景下改进BRCA检测的分子策略。